Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
NCT06627712Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2024
- Primary completion
- Nov 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological Complete Response. Started Nov 2024; status: recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06627712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627712.